Tracking the dynamics of antibody production against the SARS-CoV-2 virus after two doses of the mRNA vaccine BNT162b2

Czech version

Authors: M. Malý ¹; A. Fialová ^1,2; H. Zákoucká ¹; V. Němeček ¹; H. Orlíková ^1,2; J. Kynčl ^1,2; R. Limberková ¹
Authors‘ workplace: Státní zdravotní ústav, Praha ¹; 3. lékařská fakulta Univerzity Karlovy, Praha ²
Published in: Epidemiol. Mikrobiol. Imunol. 74, 2025, č. 1, s. 44-52
Category: Original Papers
doi: https://doi.org/10.61568/emi/11-6445/20250128/139686

Overview

Objective: An observational study was conducted from 2021 to 2022 to track the dynamics of the production of IgG antibody against the SARS-CoV-2 S protein in individuals vaccinated with two doses of the Pfizer-BioNTech mRNA vaccine BNT162b2 (Comirnaty). The study included a group of volunteers without any previous signs of SARS-CoV-2 infection as well as a group with a history of natural COVID-19 infection. The primary objective was to monitor antibody levels up to 12 months after the second dose and determine the proportion of vaccinated individuals who underwent seroconversion. The study also evaluated cases of vaccine failure within 13 months post-vaccination.

Methods: Before the vaccination began, participants had laboratory tests for IgG antibodies against the SARS-CoV-2 S protein, and their medical history related to COVID-19 was taken. Based on negative test results, a cohort of immunologically naïve individuals was formed and subsequently vaccinated with two doses of BNT162b2 (Comirnaty). Venous blood samples were collected at six time points: before the first dose, 2–3 weeks after the first dose, one month after the second dose, 3–4 months after the second dose, 6 months after the second dose, and 12 months after the second dose. A supplementary cohort included volunteers with positive antibody findings or confirmed COVID-19 infection. In some of these individuals, the dynamics of post-vaccination antibody response was also monitored. Participants filled out monthly questionnaires about respiratory infection symptoms to detect vaccine failure.

Results: The study included 166 participants who did not have SARS-CoV-2 S protein antibodies prior to vaccination. The median age was 52 years, with a higher proportion of women (71.1%). After the first and second doses of the vaccine, antibody levels showed a significant increase, followed by a gradual decline over 12 months. Seroconversion occurred in all participants except for one immunosuppressed individual. The vaccine failure rate against COVID-19 within 12 months was 13.3%.

The second cohort included 60 participants with prior SARS-CoV-2 infection. In this group, post-vaccination antibody levels increased significantly, more than in individuals without prior infection. The second dose did not result in further statistically significant increase in antibody levels for this cohort.

Conclusions: The study confirmed that the BNT162b2 mRNA vaccine induces a strong antibody response, with the majority of participants experiencing seroconversion after the first dose. Older individuals exhibited a lower antibody response, highlighting the importance of booster doses.

In individuals with prior SARS-CoV-2 infection, antibody levels were significantly higher after the first vaccine dose than in naïve individuals. These findings add to understanding antibody response dynamics and suggest the need for further research focused on optimizing vaccination schedules.

Keywords:

COVID-19 – seroconversion – IgG antibodies against SARS-CoV-2 S protein – mRNA vaccine BNT162b2

Sources

ČSÚ, Covid-19 v roce 2021 usmrtil 25,5 tisíce obyvatel Česka [online]. 2021 [cit. 2024-08-07]. Dostupné na www: https://csu.gov. cz/produkty/covid-19-v-roce-2021-usmrtil-255-tisice-obyvatel-ceska
ČSÚ, Covid-19 byl vloni druhou nejčastější příčinou smrti [online]. 2022 [cit. 2024-08-07]. Dostupné na www: https://csu.gov. cz/produkty/covid-19-byl-vloni-druhou-nejcastejsi-pricinou-smrti
Msemburi W, Karlinsky A, Knutson V, et al. The WHO estimates of excess mortality associated with the COVID-19 pandemic. Nature, 2023;613:130–137. doi: 10.1038/s41586-022-05522-2.
Meyerowitz EA, Richterman A, Bogoch II, et al. Transmission of SARS-CoV-2: A review of viral, host, and environmental factors. Ann Intern Med, 2021;174(1):69-79. doi: 10.7326/M20-5008.
Zhan M, Qin Y, Xue X, et al. Death from COVID-19 of 23 health care workers in China. N Engl J Med, 2020;382(23):2267-2268. doi: 10.1056/NEJMc2005696.
Godfred-Cato S, Bryant B, Leung J, et al. COVID-19–associated multisystem inflammatory syndrome in children—United States, March–July 2020. MMWR Morb Mortal Wkly Rep, 2020;69(32):1074-1080. doi: 10.15585/mmwr.mm6932e2.
Meslé MMI, Brown J, Mook P, et al. Estimated number of lives directly saved by COVID-19 vaccination programmes in the WHO European Region from December, 2020, to March, 2023: a retrospective surveillance study. Lancet Respir Med, 2024;12(9):714727. doi: 10.1016/S2213-2600(24)00179-6.
Thomas SJ, Moreira ED Jr, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med, 2021;385(19):1761-1773. doi: 10.1056/NEJMoa2110345.
Krzywinski M, Altman N. Visualizing samples with box plots. Nat Methods, 2014;11:119–120. doi: 10.1038/nmeth.2813.
Lustig Y, Sapir E, Regev-Yochay G, et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lancet Respir Med, 2021;9(9):999-1009. doi: 10.1016/S2213-2600(21)00220-4.
Amodio E, Capra G, Casuccio A, et al. Antibodies Responses to SARS-CoV-2 in a Large Cohort of Vaccinated Subjects and Seropositive Patients. Vaccines (Basel), 2021;9(7):714. doi: 10.3390/ vaccines9070714.
Notarte KI, Guerrero-Arguero I, Velasco JV, et al. Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review. J Med Virol, 2022;94(7):2939-2961. doi: 10.1002/jmv.27688.
Favresse J, Bayart JL, Mullier F, et al. Antibody titres decline 3-month post-vaccination with BNT162b2. Emerg Microbes Infect, 2021;10(1):1495-1498. doi: 10.1080/22221751.2021.1953403.
Carrat F, Villarroel PMS, Lapidus N, et al. Heterogeneous SARS-CoV-2 humoral response after COVID-19 vaccination and/or infection in the general population. Sci Rep, 2022;12(1):8622. doi: 10.1038/s41598-022-11787-4. Erratum in: Sci Rep, 2022;12(1):9405. doi: 10.1038/s41598-022-13938-z.
Takahashi T, Ellingson MK, Wong P, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature, 2020;588(7837):315-320. doi: 10.1038/s41586-020-2700-3.
Müller L, Andrée M, Moskorz W, et al. Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination. Clin Infect Dis, 2021;73(11):2065-2072. doi: 10.1093/cid/ ciab381.
Wei J, Stoesser N, Matthews PC, et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nat Microbiol, 2021;6(9):1140-1149. doi: 10.1038/s41564-021-00947-3
Miková E., Szabóová K., Bunčák M., et al. Monitoring hladiny protilátok v súvislosti s očkovaním proti SARS-CoV-2 – 11-mesačné sledovanie. Epidemiol Mikrobiol Imunol, 2023;72(3):127-139.
Wang X, Zein J, Ji X, et al. Impact of vaccination, prior infection, and therapy on Omicron infection and mortality. J Infect Dis, 2023;227(8):970-976. doi: 10.1093/infdis/jiac460.
Lin DY, Gu Y, Wheeler B, et al. Effectiveness of Covid-19 vaccines over a 9-month period in North Carolina. N Engl J Med, 2022;386(10):933-941. doi: 10.1056/NEJMoa2117128.
Goel RR, Apostolidis SA, Painter MM, et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. Sci Immunol, 2021;6(58): eabi6950. doi: 10.1126/sciimmunol.abi6950.
Stamatatos L, Czartoski J, Wan YH, et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science, 2021;372(6549):1413-1418. doi: 10.1126/science.abg9175.
Perkmann T, Perkmann-Nagele N, Koller T, et al. Serum antibody response to BNT162b2 after natural SARS-CoV-2 infection. Eur J Clin Invest, 2021;51(11):e13632. doi: 10.1111/eci.13632.
Salvaggio M, Fusina F, Albani F, et al. Antibody response after BNT162b2 Vaccination in Healthcare Workers Previously Exposed and Not Exposed to SARS-CoV-2. J Clin Med, 2021;10(18):4204. doi: 10.3390/jcm10184204.
Brisotto G, Muraro E, Montico M, et al. IgG antibodies against SARS-CoV-2 decay but persist 4 months after vaccination in a cohort of healthcare workers. Clin Chim Acta, 2021;523:476-482. doi: 10.1016/j.cca.2021.10.035.
Ebinger JE, Fert-Bober J, Printsev I, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med, 2021;27(6):981-984. doi: 10.1038/ s41591-021-01325-6.
Saadat S, Tehrani ZR, Logue J, et al. Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2. JAMA, 2021;325(14):14671469. doi: 10.1001/jama.2021.3341.